Kuehn Law Investigates Regenxbio Inc. Officers and Directors
Kuehn Law is investigating Regenxbio Inc. officers and directors for alleged fiduciary duty breaches. Investors who purchased RGNX stock before February 9, 2022, are urged to contact the firm.
Shareholder litigation law firm Kuehn Law, PLLC announced an investigation into potential breaches of fiduciary duty by certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX). The probe centers on allegations related to the company's gene therapy RGX-111.
According to a federal securities lawsuit, Regenxbio allegedly provided investors with false or misleading information regarding the efficacy and safety of its RGX-111 clinical trial. The suit claims the company made positive assertions about the future success of RGX-111 based on preliminary data from an ongoing Phase I/II study.
Kuehn Law is seeking to hear from current RGNX shareholders who purchased stock prior to February 9, 2022. The firm stated that shareholders should contact them promptly as there may be a limited time to assert their rights.
The law firm covers all case costs and does not charge investor clients. Kuehn Law emphasized the importance of shareholder participation in upholding the integrity and fairness of the financial markets.